biostudies-literaturePreston MANHLBI NIH HHSNCI NIH HHS2705-11https://www.ebi.ac.uk/biostudies/studies/S-EPMC5019757biostudies-literatureUnknown34(23)<h4>Purpose</h4>Prostate-specific antigen (PSA) level in midlife predicted future prostate cancer (PCa) mortality in an unscreened Swedish population. Our purpose was to determine if a baseline PSA level during midlife predicts lethal PCa in a US population with opportunistic screening.<h4>Materials and methods</h4>We conducted a nested case-control study among men age 40 to 59 years who gave blood before random assignment in the Physicians' Health Study, a randomized, placebo-controlled trial of aspirin and β-carotene among 22,071 US male physicians initiated in 1982 and then transitioned into a prospective cohort with 30 years of follow-up. Baseline PSA levels were available for 234 patients with PCa and 711 age-matched controls. Seventy-one participants who developed lethal PCa were remJournal of clinical oncology : official journal of the American Society of Clinical OncologyBaseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.PMC5019757P50 CA092629R01 HL034595P30 CA008748R01 CA097193R01 CA040360R01 CA034944R01 HL026490R33 CA127768P50 CA090381Wilson KMPreston MAFeldman ASSesso HDKibel ASSjoberg DDGerke TDahl DMMucci LACarlsson SVBatista JLGann PHVickers AJfalseBaseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.<h4>Purpose</h4>Prostate-specific antigen (PSA) level in midlife predicted future prostate cancer (PCa) mortality in an unscreened Swedish population. Our purpose was to determine if a baseline PSA level during midlife predicts lethal PCa in a US population with opportunistic screening.<h4>Materials and methods</h4>We conducted a nested case-control study among men age 40 to 59 years who gave blood before random assignment in the Physicians' Health Study, a randomized, placebo-controlled trial of aspirin and β-carotene among 22,071 US male physicians initiated in 1982 and then transitioned into a prospective cohort with 30 years of follow-up. Baseline PSA levels were available for 234 patients with PCa and 711 age-matched controls. Seventy-one participants who developed lethal PCa were rem2016-01-01T00:00:00Z2016 Aug2026-05-29T20:33:38.341Z2019-03-27T02:24:00ZS-EPMC50197572729840410.1200/jco.2016.66.752710.1200/JCO.2016.66.7527